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ABSTRACT: Three patients had marked marrow fibrosis and an apparent Philadelphia (Ph) chromo- 
some. Hematologic, cytogenetic, and molecular studies demonstrated the heterogeneity of such cases, 
including the first example  of clinically typical myelofibrosis (MF) associated with a bcr gene rear- 
rangement characteristic of chronic myelogenous leukemia (CML). 
INTRODUCTION 
Many cases of Ph i lade lph ia  chromosome-posi t ive  (Ph-) 
chronic myelogenous  leukemia (CML) have some increase 
in ret iculin fibers in the bone marrow (BM), and some also 
have increased depos i t ion  of collagen, par t icular ly  late in 
the cl inical  course [1]. Rarely, however,  does a patient 
with Ph ' disease have the cl inical  and hematologic pic- 
ture of typical  myelofibrosis  (MF), as currently defined [2-  
5]. We report  two such patients and a third Ph" patient 
with sufficient marrow fibrosis to confuse the initial diag- 
nosis. 
CASE REPORTS 
Case 1 (P.W.) 
A 45-year old woman was noted to be anemic; in February 
1989 during hospi ta l iza t ion for a herniated disc. Subse- 
quent s tudies showed a hemoglobin level of 8.8 g/dl, a 
white blood cell (WBC) count of 8.8 x 109/L, and a platelet 
count of 987 x 109/L. The peripheral  blood (PB) smear 
showed nucleated red blood cells (RBC), teardrop forms, 
schistocytes,  and a few immature  leukocytes.  Platelets 
were increased,  with megakaryocyte fragments. A BM bi- 
opsy showed marked increase in fibrosis, megakaryocytic 
hyperplas ia ,  and markedly  increased reticulin. The leuko- 
cyte alkal ine phosphatase  (LAP) level was 6 (normal = 
27-67).  A cl inical  diagnosis  of MF was made. Cytogenetic 
and molecular  genetic: s tudies  were made of the BM at that 
time. 
She was entered on an MF protocol involving treatment 
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with interferon (IFN) daily,  result ing in marked improve- 
ment in hemoglobin and platelet  levels. In Apri l  1990, she 
received a BM transplant  from a sibling and current ly (July 
1991) has no evidence of her pr imary disease. 
Case 2 (S.S.) 
A 61-year-old man was first s tudied in London in Decem- 
ber 1986 because he had dyspnea  on exertion and ankle 
edema. He had a hemoglobin  level of 8.4 g/dl, a WBC 
count of 16 × 109/L, and a platelet  count of 1,500 × 10Y/L. 
The PB smear  showed basophil ia ,  anisocytosis,  and tear- 
drop forms. Bone marrow biopsy showed panmyelosis ,  
is lands of blasts, and increased ret iculin fibers, considered 
to represent "agnogenic  myelo id  metaplasia  with myelofi- 
brosis." The LAP was not determined.  During the next 2½ 
years, he was treated at several inst i tut ions in the United 
Kingdom and the United States, requiring increasingly fre- 
qJent  transfusions.  The cl inical  and hematologic diagno- 
sis of MF was confirmed on at least two subsequent occa- 
sions by repeat BM examinat ion,  including one in 
September  1989, when cytogenetic and molecular  genetic 
studies were also performed. The cl inical  course remained 
general ly unchanged,  with suppor t ive  therapy and with- 
out progression to acute leukemia,  until  the pat ient 's  
death owing to cardiac compl ica t ions  in February 1991. 
Case 3 (J.F.) 
A 55-year-old woman was s tudied in December 1989 be- 
cause of fatigue, weight loss, and lower-leg edema. 
Splenomegaly  was noted. Her hemoglobin was 7.6 g/dl, 
and the WBC count was 93 × 109/L (28% segments, 14% 
bands, 4% lymphocytes ,  1% monocytes,  7% eosinophils ,  
13% basophils ,  9% atypical  lymphocytes ,  7% metamyelo- 
cytes, 14% myelocytes,  2% promyelocytes ,  and 1% blasts). 
The platelet  count was 613 x 109/L. The PB smear showed 
nucleated RBC, with occasional  teardropping and large 
platelet  forms. The LAP was 26. Bone marrow biopsy 
showed greatly increased numbers  of megakaryocytes and 
areas of marked fibrosis al ternating with other areas of 
marked hyperplas ia ,  with nests of cells that appeared  to be 
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blasts. Chromosome studies were made of the BM in Janu- 
ary 1990, and the patient was then treated with hydroxy- 
urea, with normalizat ion of her WBC and platelet counts. 
Since February 1990, she has been part icipat ing in a long- 
term protocol involving treatment with IFN, and her dis- 
ease has been stable. Repeat chromosome studies were 
performed in May, August,  and November 1990, with mo- 
lecular s tudies also perfornted on the latter spe(:imen. 
MATERIALS AND METHODS 
For chromosome studies,  s tandard G-banded preparat ions 
were macie from BM or PB specimens culturect for 24 
hours without  mitogen [6]. 
To determine  the involvement  of the bcr locus, DNA 
from cases 1 and 3 was hybr id ized with both a partial 
eDNA probe [71 and a genomic probe [Oncogene Science) 
for the bcr major breakpoint  cluster region [8]. For case 2, 
RNA was extracted from glass sl ide smears of BM, anct 
PCR amplif icat ion studies for bcr-abl chimeric mRNA 
were performed, as describect previously [9]. Controls in- 
c luded a known posit ive CML specimen,  vvhich showed 
evidence of bcr-abl mRNA; appropr ia te  negative controls; 
and analysis  of the patient sample  for (:-abl mRNA, which 
demonstra ted that intact mRNA hac| indeed been isolated 
from the glass sl ide specimen.  
RESULTS 
As indicated in Table 1 and Fig. 1, all BM cells from case 1 
had the karyotype 46,XX,t(9;22)(q34;q11),del(20)(q12). 
The molecular  s tudies showed a single rearranged bcr al- 
lele with EcoRl, BamHI, and Bglll enzymes.  The pattern 
suggested that the breakpoint  was located in the F2 or F3 
region of Sbtalr id [10], toward the 3' end of the major 
breakpoint  region of typic:al CML. 
In case 2, al though the c:ytogenetic abnormali t ies  in- 
volved the same three (:hromosomes as in case 1, with an 
apparent  Ph chromosome,  there was not actually a t{9:22). 
As indicated in Table 1 and Fig. 2. the karyotype was 
interpreted as 46,XX,t[20;22)(p13;q11},del(9)[q34}. All 
metaphases examined were abnormal,  and approximate ly  
one third were polyploid ,  with the same chromosome ab- 
errations. The possibi l i ty  of a "masked"  bcr-abl transloca- 
tion was (:onsidered, but the PCR amplif icat ion studies 
provided no evidence of b(:r-abl chimeric  mRNA. 
In case 3, the original (:hromosome study, performed at 
another insti tution, demonstra ted a Ph chromosome, and 
our subsequent  three studies of BM and PB, summarized 
in Table 1, confirmed the karyotype of the neoplastic: (:ells 
as 46,XX,t(9;22)(q34;q11). All metaphases were abnormal 
and, as with case 2, a proport ion were polyploid ,  (:onsis- 
tent with the observed megakaryocytosis  and thrombocy- 
tosis. As in case 1, molecular  s tudies for bcr involvement 
showed a single rearranged bcr allele with both the BamHl 
and BglIl enzymes.  In this case, the pattern indicated that 
the breakpoint  was located in the F1 region, toward the 5' 
end of the major breakpoint  region. 
DISCUSSION 
These three cases i l lustrate a variety of ways in which 
severe marrow fibrosis may be associated with a Ph chro- 
mosome. The first case represents the rare c i rcumstance in 
which the karyotypic  abnormali t ies  in a patient with typi- 
cal MF in(:lude the characterist ic  t(9;22) usual ly associ- 
ated with CML. Only one such case is listed in the 1988 
Mitelman catalogue [4], and a few others have been de- 
scribed in earl ier  articles [2, 3]. None have been previously 
s tudied for b(:r rearrangement.  The fibrous proliferation in 
MF is not part of the preneoplas t ic  or neoplast ic  (:lone, but 
is apparent ly  s t imulated by products  of the abnormal he- 
roic cells, par t icular ly  platelet-derived growth factor 
(PDGF) [5, 11, 12]. This helps to explain the coexisten(:e of 
megakaryo(:ytosis and marrow fibrosis in this (:as(;, as well 
as in (:ase 3, al though it is not known what genetic altera- 
tion, if any, in the neoplastic: cells, other than the bcr-abl 
transh)cation contributes to this phenomenon.  In case 1, 
the del(20q) abnormal i ty  may have contr ibuted to the spe- 
(:ific phenotype,  t towever,  al though this alteration does 
occur nonrandomly  in MF, it has also been associated with 
a variety of other myeloprol i ferat ive and mvelodysplas t ic  
disorders  [4, 5, 13-16],  as well as with some cases (if Ph '  
CML without  significant MF [17, 18]. There has been re- 
cent spe(:ulation that this del[20)(q13) abnormali ty  might 
spe(:ifically involve the hck gene (C. Willman,  personal 
communicat ion) ,  whi(:h maps to this region and codes for 
a tyr()sine kinase, but this has not been confirmed, and in 
this t)articular case no rearrangement of the hck gene was 
detected on s tandard Southern blots {K. l luebner, personal 
communicat ion) .  
The second case was also considered typical  MF when 
s tudied clini(:ally and hematological ly  at a number of 
medical  centers in the United States and the United King- 
Table 1 Cytogenetic anti molecular  findings 
No. of b(:r-ubl 
Patient Dale Slm(:imen metaphase.s Karyotype Rearrangement 
1 (P. W.) 2/1989 Marrow 25 46,XX,t(9:22){q34:qll).del(20)(q12) Positive 
2 (S. S.) 9/1989 Marrow :30"  46,XY,9(20:22)(pl 3:ql 1 ],del[.q)(q341 Negative 
3 (]. F.) 6"1990 Marrow 25" 46,XX,t(9:22][q34;q11) 
9/19.()0 Marrow 12 46,XX,t(9:22](q34:ql 1) 
12/1990 Blood 25" 46,XX,t(9:221(q34:q 11 ) Positiv(~ 
" "l'ml to 30% telrap]oid 
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Representative karyotype from marrow of patient 1 (P.W.): 46,XX,t(9;22)(q34:q11),c|el(20)(q12). 
dom. The karyotype also appeared  ini t ial ly to contain a Ph 
chromosome.  However,  both cytogenetic and molecular  
analysis  indicated that there was not a bc:r-abl transloca- 
tion, but instead an unusual  t(20:22)(p13;qll) ,  as well as a 
small  delet ion from the terminal  port ion of the long arm of 
one chromosome 9. The t(20;22) has not previously been 
described in myeloprol i fera t ive  or myelodysplas t ic  disor- 
ders, but there have been at least two reported cases of Ph ~ 
CML with t ranslocat ions involving the short arm of chro- 
mosome 20, al though nei ther  was confirmed at the molec- 
ular level as having a bcr rearrangement.  In one instance, 
the t ranslocat ion was descr ibed as t(9;20;22)(q34;p11- 
13;q11) [19], and in the other a s ' s imply  t(20;22)(p12;q11) 
[20]. Because of the overall  rarity in hemic disorders of 
these rearrangements involving 20p, speculat ing about 
their significance is difficult. 
Figure 2 Representative karyotype froln marrow of patient 2 (S.S.): 46,XY,t(20:22)(p13;qlll,del(9)(q34). 
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T h e  t h i rd  case  exem pl i f i e s  a s o m e w h a t  more  c o m m o n  
en t i t y  in the  s p e c t r u m  of d i s o r d e r s  tha t  range  f rom typ ica l  
CML w i t h  m i n o r  degrees  of m a r r o w  f ibrosis  a n d / o r  mega-  
ka ryocy tos i s  to Ph * cases  in i t i a l ly  a p p e a r i n g  as typ ica l  
e s sen t i a l  t h r o m b o c y t h e m i a  (ET) w i t h  m a r k e d  inc rease  in 
m e g a k a r y o c y t e s  a n d  p la t e l e t s  ant i  w i t h  s o m e  degree  of 
m a r r o w  f ibrosis  [21, 22]. T h i s  p a r t i c u l a r  case  was  u n u s u a l  
in tha t  the  s eve r i t y  of the  f ibrosis  c o m p l i c a t e d  the  o r ig ina l  
d iagnos i s ,  r a i s ing  a q u e s t i o n  of w h e t h e r  the  pa t i en t  s h o u l d  
be c o n s i d e r e d ,  a n d  m a n a g e d ,  as h a v i n g  MF or CML. T h e s e  
t h r ee  cases  i n d i c a t e  the  n e e d  for carefu l  e v a l u a t i o n ,  in- 
c l u d i n g  a p p r o p r i a t e  cy t ogene t i c  and  m o l e c u l a r  s tud ies ,  of 
all p a t i e n t s  w h o  in i t i a l ly  h a v e  severe  m a r r o w  fibrosis ,  as 
t r e a t m e n t  o p t i o n s  are  c o n s i d e r e d .  
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